Natera (NTRA) Lifted to Hold at BidaskClub

Share on StockTwits

Natera (NASDAQ:NTRA) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Monday.

Other research analysts also recently issued reports about the stock. Canaccord Genuity reissued a “buy” rating and issued a $25.00 target price on shares of Natera in a research report on Monday, March 11th. ValuEngine downgraded shares of Natera from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 9th. Finally, Zacks Investment Research raised shares of Natera from a “sell” rating to a “hold” rating in a research report on Friday. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $27.75.

Natera stock opened at $19.40 on Monday. The company has a market capitalization of $1.20 billion, a PE ratio of -9.02 and a beta of 1.84. The company has a current ratio of 2.44, a quick ratio of 2.32 and a debt-to-equity ratio of 1.30. Natera has a fifty-two week low of $8.60 and a fifty-two week high of $29.62.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, March 12th. The medical research company reported ($0.51) earnings per share for the quarter, hitting the consensus estimate of ($0.51). The business had revenue of $67.00 million for the quarter, compared to the consensus estimate of $62.87 million. Natera had a negative net margin of 49.72% and a negative return on equity of 1,214.02%. On average, equities research analysts predict that Natera will post -1.59 earnings per share for the current fiscal year.

In related news, insider Jonathan Sheena sold 23,356 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $20.51, for a total transaction of $479,031.56. Following the transaction, the insider now directly owns 294,758 shares of the company’s stock, valued at $6,045,486.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Burkes Brophy sold 3,192 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $16.00, for a total transaction of $51,072.00. Following the transaction, the chief financial officer now directly owns 13,422 shares in the company, valued at $214,752. The disclosure for this sale can be found here. Insiders have sold 40,194 shares of company stock worth $742,949 over the last ninety days. 13.18% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Great West Life Assurance Co. Can grew its position in Natera by 136.8% during the fourth quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock valued at $80,000 after purchasing an additional 3,420 shares in the last quarter. Legal & General Group Plc lifted its stake in Natera by 14.5% in the fourth quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock valued at $81,000 after acquiring an additional 736 shares during the last quarter. Pacer Advisors Inc. acquired a new stake in Natera in the third quarter valued at approximately $106,000. Point72 Hong Kong Ltd acquired a new stake in Natera in the third quarter valued at approximately $119,000. Finally, Quantbot Technologies LP acquired a new stake in Natera in the third quarter valued at approximately $135,000. 90.05% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: Return on Equity (ROE)

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

StableUSD Reaches Market Capitalization of $5.90 Million
StableUSD Reaches Market Capitalization of $5.90 Million
Unikoin Gold  Hits 24-Hour Trading Volume of $13,765.00
Unikoin Gold Hits 24-Hour Trading Volume of $13,765.00
VapersCoin Price Hits $0.0000 on Major Exchanges
VapersCoin Price Hits $0.0000 on Major Exchanges
Financial Contrast: RLJ Lodging Trust  vs. Gecina
Financial Contrast: RLJ Lodging Trust vs. Gecina
$0.21 Earnings Per Share Expected for Garrison Capital Inc  This Quarter
$0.21 Earnings Per Share Expected for Garrison Capital Inc This Quarter
Paylocity Holding Corp  Expected to Announce Earnings of $0.59 Per Share
Paylocity Holding Corp Expected to Announce Earnings of $0.59 Per Share


© 2006-2019 Ticker Report